Related Experiment Video

Updated: Jun 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in

Wei Wei1, Yu Fan, Hongyu Liu

  • 1Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 18, 2010
PubMed
Abstract

Insights

Lung cancer cell lines show varying resistance to gefitinib. EGFR gene mutations and expression levels correlate with this acquired drug resistance, impacting treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Gefitinib is a targeted therapy for non-small cell lung cancer (NSCLC).
  • Understanding drug resistance mechanisms is crucial for optimizing NSCLC treatment.
  • Cell line models are essential for studying drug response and resistance.

Purpose:

  • To investigate differential gefitinib drug resistance among human lung cancer cell lines.
  • To elucidate the molecular mechanisms underlying gefitinib resistance.
  • To correlate EGFR gene alterations with gefitinib sensitivity/resistance.

Summary:

  • Four lung cancer cell lines (PC9, PC9/AB2, PC9/AB11, PC9/BB4) were analyzed for gefitinib resistance.
  • EGFR gene sequencing revealed a 15 bp deletion in exon 19 in all lines and an A-to-G mutation in exon 20 in PC9/AB11.
  • Real-time PCR showed significantly higher EGFR mRNA levels in the gefitinib-sensitive PC9 cell line compared to resistant lines.

Impact:

  • Identifies distinct gefitinib resistance profiles in lung cancer cell lines.
  • Suggests a correlation between EGFR gene mutations, expression levels, and acquired gefitinib resistance.
  • Provides a basis for further research into overcoming gefitinib resistance in NSCLC.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...